Oncology Business Management | Specialty

FDA Grants Priority Review to New Indication for Abiraterone Acetate

August 29th 2012

The FDA announced that Priority Review has been granted to abiraterone acetate for certain advanced prostate cancer cases based on positive data presented at the ASCO annual meeting.

Drug Shortage Dilemma: Trying New Tactics in a Tough Arena

August 29th 2012

Fresh strategies for grappling with the chronic, and at times critical, shortages of cancer drugs that have frustrated the oncology community for the past decade are likely to help alleviate supply problems.

Identification and Prevention of Skeletal-Related Events

August 27th 2012

Immunotherapy for Castration-Resistant Prostate Cancer

August 27th 2012

Optimal Treatment Sequencing for Advanced Prostate Cancer

August 27th 2012

Therapeutic Options for Advanced Prostate Cancer

August 27th 2012

Evidence-Based Care for Localized Prostate Cancer

August 27th 2012

Deciding Treatment Options for Early-Stage Prostate Cancer

August 27th 2012

Robotic-Assisted Laparoscopic Radical Prostatectomies

August 27th 2012

Prostate Cancer Screening and Early Detection, Part III

August 27th 2012

Prostate Cancer Screening and Early Detection, Part I

August 27th 2012

Prostate Cancer Screening and Early Detection, Part II

August 27th 2012

Moore's Law Meets Goldilocks

August 23rd 2012

To be transformative, we need to think outside the box, and maybe it will take a computer visionary and a fairytale to guide us.

Economic Factors Affecting Supportive Care

August 23rd 2012

Research is needed to justify the dollar savings achieved by a supportive care program, but it is not clear what should be measured and how studies should be designed to demonstrate this.

Elaine Mardis on Sensitivity to Aromatase Inhibitors

August 20th 2012

Elaine Mardis, from the Genome Institute at Washington University School of Medicine, on Sensitivity to Aromatase Inhibitors

Newly Published Results Show Survival Benefit with Enzalutamide in Prostate Cancer

August 16th 2012

The novel drug enzalutamide (formerly MDV3100) significantly improved overall survival in men with metastatic castrate-resistant prostate cancer (mCRPC).

Myriad Genetics Maintains BRCA1 and BRCA2 Patents, Appellate Court Rules

August 16th 2012

On August 16, the US Federal Circuit Court of Appeals ruled 2-1 to uphold its original decision that Myriad Genetics has the right to hold the patent to the BRCA1 and BRCA2 genes.

Cancer Management Systems: A Path Toward Better Patient Care

August 15th 2012

Oncologists are all faced with the same challenge-delivering the best cancer care possible while reining in rising costs and one answer that many oncologists are looking at is cancer management systems.

Dr. Herbst Explores Molecular Testing in Lung Cancer

August 15th 2012

Dr. Roy S. Herbst, from Yale Cancer Center, Explores Molecular Testing in Lung Cancer

Ranking Value in Cancer Care: Analysis of a "Pathways" Approach

August 13th 2012

Amid a continuing debate over healthcare spending in the United States, the oncology community is growing more introspective about the costs associated with increasingly sophisticated cancer therapeutics.